Society is evolving rapidly in the information age. Portable electronic devices enable access to global knowledge at literally every step: we check the weather on an app, monitor what is happening around the world through online news feeds, and connect with family and friends through social networking services. The immediate availability of a broad range of knowledge sources has led to greater health awareness in the general population. Individuals are increasingly using wearable devices to monitor sleep, activity levels, glucose levels or heart function to identify abnormalities of potential health concern [1] [2] [3] . Since the first complete human genome sequences were published 15 years ago 4, 5 , technological advances and cost savings in DNA sequencing have enabled millions of people to have their individual genomic sequence analysed, primarily within the settings of research studies or clinical care. Each individual harbours four to five million variants in their genome that collectively differentiate one person from another 6 . Some of these variants have no health effect, whereas others increase or lower the risk of disease. There is widespread recognition that access to an individual's genomic sequence and other 'omics' data can enable a more detailed understanding of our health and disease risks, and inform a more precise approach to patient care, a strategy now commonly called 'precision medicine' (REFS 7, 8) .
Jewish descent to be screened for carrier status either before a couple begins dating or during prenatal counselling; for example, through specialized organizations such as Dor Yeshorim. The Ashkenazi Jewish population is well known to have a high risk of certain genetic diseases due to high carrier rates, such as 1 in 15 for type 1 Gaucher disease (Online Mendelian Inheritance in Man (OMIM) #230800) and 1 in 27 for Tay-Sachs disease 9 (OMIM #272800). For a given couple, if both individuals are found to carry a pathogenic variant in the same gene for a recessive disease, then there is a 25% risk of having an affected child (FIG. 1, Case study 1). In this scenario, the couple may be encouraged to seek other relationships, pursue in vitro fertilization with selected non-affected embryos, or at least be informed of their reproductive risks.
Certain disorders are common to specific ethnic populations, whereas other disorders such as cystic fibrosis (OMIM #219700) are common across all populations, leading to broad recommendations for genetic screening 10 . It is now becoming increasingly common in the United States to screen for a broad array of recessive conditions during preconception counselling to determine the risk for a future pregnancy. As such, these tests now routinely include the detection of pathogenic variants in a hundred or more genes. Several companies (such as Counsyl and Good Start Genetics) are primarily focused on this market, whereas others are adding such testing as one of the many genetic and genomics tests in their arsenal of services. Most services report carrier status independently for each partner, other companies (such as Gene Peeks) focus on a joint analysis, confining the report to only disorders in which both couples are positive for carrier status, a much rarer event.
Millions of couples have already pursued carrier screening, making it one of the most common indications for genetic testing.
Most preconception genetic testing is focused on detecting carrier status for monogenic diseases such as cystic fibrosis; however, business opportunities in the direct-to-consumer (DTC) market are increasing. Thus, it is unsurprising With genomic data now increasingly used to guide the individual care of patients, our health care systems are evolving, although several challenges remain. This Perspective considers how genomics is guiding health care for the individual, providing illustrative examples of how individuals are taking advantage of personal genomic information, ranging from advanced diagnostics and tumour profiling to genomic risk assessments. These examples are then interweaved with the day-to-day challenges still facing the integration of genomics into clinical practice as well as with strategies that are being developed to overcome these barriers and enable genomics to be a part of ever more aspects of everyday patient care.
that online dating services are bringing genomics onto the scene. Primarily based on early studies of the role of the immune system in choosing a mate 11 , companies such as Instant Chemistry or Gene Partner are now offering genetic testing as a companion service to online dating, using genetics to rate compatibility. Although chromosomal abnormality suggested by ultrasound findings or advanced maternal age. In rarer cases, testing was performed for a known familial pathogenic variant for a disorder previously identified in the family. Although both approaches are still offered, couples are also pursuing routine chromosome microarray (CMA) testing, even a novelty in the market, there is still little evidence of the validity of genomics in forming successful human relationships.
Prenatal testing. Prenatal genetic testing has been offered for more than 60 years 12 .
Testing initially focused on karyotyping, often on the basis of heightened risk of a Case study 2: Sofia is pregnant with her first child. Wanting to do everything to ensure a healthy newborn, she opts for whole-exome sequencing. The sequencing results identify pathogenic variants in PKU, which have been associated with phenylketonuria. Armed with this information, Sofia immediately begins a low-phenylalanine diet during pregnancy and arranges for the availability of a special dietary infant formula to avoid neonatal exposure to phenylalanine. With this treatment plan, the baby is expected to develop normally and lead a healthy adult life.
Case study 1: Bob and Julie are considering having a child and seek preconception genetic testing. Julie is found to carry seven pathogenic variants for recessive diseases and Bob is found to carry five. There is one gene, SMN1, for which both are carriers. This result puts the couple at a 25% risk of having a child with spinal muscular atrophy, a progressive muscle-wasting disease. Julie and Bob decide to pursue preimplantation genetic diagnosis to avoid a pregnancy with an affected fetus by selecting embryos that do not inherit both pathogenic variants.
Case study 3: Mei has just given birth to a healthy baby girl. She decides to have her daughter's genome assessed using exome sequencing. This test reveals two pathogenic variants in GJB2, putting the newborn at risk of hearing loss that can be progressive. Although the child passed a newborn baby hearing screening test, a diagnostic audiological test reveals mild hearing loss, often missed in newborn screening. The baby is fitted with hearing aids to facilitate normal auditory development. The baby's hearing is monitored yearly, and if it progresses to profound deafness, the option for cochlear implantation surgery can be offered to the family.
Case study 6: John had watched his father suffer a long end-of-life battle with Alzheimer disease. Curious about his own risks, he elected to obtain genetic testing through a direct-to-consumer testing company and learned that he harbours two copies of the APOE ε4 variant, putting him at heightened risk of Alzheimer disease. He also learned that his ancestral origins were more diverse than he had previously realized and was able to connect with several distant relatives though an online ancestry portal.
Case study 4: Joseph was interested in pursuing genomic sequencing to learn about his own health risks. He ordered a whole-genome sequencing test through a medical geneticist offering concierge services and discovered that he harbours a pathogenic variant for hypertrophic cardiomyopathy. This finding prompted a cardiac evaluation, which revealed normal cardiac morphology and conduction systems; however, a detailed family history assessment identified suspicion for hereditary sudden cardiac death on his mother's side based on unexplained drowning of a sibling and two maternal uncles who died of heart attacks at 55 and 60 years of age. Given the incomplete penetrance of hypertrophic cardiomyopathy, Joseph's actual risk of disease is unclear, but with a positive at-risk genotype, he will pursue regular cardiac evaluations and inform family members of their possible risk.
Case study 5: Jessica is seeing a genetic counsellor (GC) to discuss her risk of breast cancer after her grandmother and aunt died of breast cancer and her mother was recently diagnosed. She brings a copy of her aunt's laboratory report from 2008 that notes a pathogenic variant identified and cites a publication to support the variant interpretation. Jessica's GC quickly looks up the variant in ClinVar and discovers that five clinical laboratories now interpret the variant as benign, citing more recent evidence accumulated from clinical testing. The GC suggests that her aunt's testing probably did not identify the correct cause of disease in her family and suggests that Jessica's mother undergo testing to identify another potential cause of hereditary breast cancer that may not have been examined in 2008. If a cause of breast cancer is found in her mother, Jessica would be able to pursue testing to inform her own risk. Nature Reviews | Genetics without a clinical indication, to screen for genetic abnormalities, including those too small to be detected by conventional karyotyping, such as submicroscopic copy number variants (CNVs). More recently, non-invasive prenatal testing has skyrocketed in its uptake given its preference over invasive amniocentesis procedures required for CMAs. However, non-invasive prenatal testing is currently only robust for detecting complete chromosomal aneuploidies such as trisomy 21, which is causative for Down syndrome 13, 14 . Although genomic sequencing of fetal DNA has been achieved through non-invasive techniques 15 , it is not commonly used given the very small amount of fetal DNA circulating in the maternal bloodstream and the difficulty in differentiating fetal DNA from maternal DNA. However, it is likely to be only a matter of time before the technology of choice includes genome sequencing, to be as comprehensive as possible in detecting disease risk in a developing fetus. Although personal decisions vary with regard to the potential option to terminate a pregnancy based on genetic testing results, many couples choose prenatal testing not to inform termination but to enable awareness of disease risk and to implement strategies to optimize newborn health. For example, awareness of risk of an inborn error of metabolism, such as phenylketonuria (OMIM #261600), would allow immediate dietary interventions at birth to improve the child's health outcome 16 (FIG. 1, Case study 2).
The reduced incidence of Tay-Sachs disease owing to carrier screening 17 provides a clear example of how preconception and prenatal testing can reduce the incidence of genetic diseases. However, the impact of broader screening on the larger collection of genetic diseases is more difficult to assess. Statistics from the US Centers for Disease Control and Prevention indicate a 6% reduction in infant mortality rate from congenital malformations between 2005 and 2011 (REF. 18 ), raising the possibility that preconception and prenatal genetic testing may have aided this reduction. However, it is also possible that improved prenatal imaging diagnostics, medical management and surgical interventions have played an equal if not larger role.
Newborn screening.
With an increasing focus on preventive health, one might consider the newborn period an ideal time for health screens. Most babies are born within a hospital setting and typically stay newborn period 24 . Approaches currently under investigation include using genomics as a rapid diagnostic tool, as well as screening healthy babies for disease risk or to inform decision-making throughout the newborn period as issues arise 25, 26 .
Findings from these studies are anticipated to become available over the next few years and will help to guide the appropriate use of genomics in the newborn period.
Newborn screening for disease risk is a developing area of genomics; however, it is important to note that one of the most valuable aspects of genetic and genomic testing today is the ability to end the diagnostic odyssey [27] [28] [29] . Countless newborn babies with multiple congenital anomalies, complex syndromes or unexplained severe neurological phenotypes are evaluated with extensive biochemical, imaging and other analytical work-ups. These diagnostic tests are often performed on an annual basis for many years, along with countless referrals to specialists. The ultimate goal is to not only make a diagnosis but to provide the family with information and tools to understand the cause of disease and enable them to avoid the costly and time-consuming work-ups within the complex distributed health care system. After a diagnosis, physicians can focus care on aspects of the disease that are manageable and intervene to prevent anticipated developments of disease known to be associated with the disorder. for 48 hours. Newborn screening takes advantage of this setting for performing an individual's first health screens after birth. Most countries have mandated newborn screening programmes, although the number of disorders for which screening is provided varies, ranging from none (for example, there are no programmes in central Africa, according to the International Society for Neonatal Screening) to more than 50 conditions (as in most states of the United States, according to the National Newborn Screening and Global Resource Center).
The criteria for adding a disorder to newborn screening are based on the availability as well as sensitivity and specificity of a screening test. Moreover, the availability of diagnostic services to make a definitive diagnosis after a screening referral, and the availability and efficacy of treatments to improve the long-term outcomes of diagnosed individuals are considered 19 . For example, the American College of Medical Genetics and Genomics has developed a framework to score each condition being considered for screening based on the following factors: the clinical characteristics of the condition; the analytical characteristics of the test; and the diagnosis, follow-up, treatment and management of the condition 19 . There is also a push to include parents as decision-makers, and to address whether any newborn screening tests should be mandatory or should allow an opt-in or opt-out decision by parents 20 . Evidence regarding long-term outcomes is often limited, and experience in the practical aspects of screening is lacking. Thus, when considering the addition of new disorders to a screen, there is also a need to ensure adequate tracking of programmes after implementation to evaluate success in achieving the goals of screening. An example of a success is the screen for phenylketonuria (FIG. 1, Case study 2) . For other disorders, such as cardiomyopathy 21 or retinoblastoma (tumour of the eye) 22 , no economical approach to screening is available; however, intervention at birth or over the course of a lifetime could still enable avoidance of adverse outcomes. As such, interest in genomic screening approaches to enable the detection of such disorders is increasing 23 . The US National Institutes of Health (NIH) have funded four projects, together forming the Newborn Sequencing in Genomic Medicine and Public Health (NSIGHT) programme, to explore the use of genomic testing in the
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In addition, many families, after obtaining a diagnosis, are motivated to build or join patient advocacy organizations, to fundraise or to enter into research programmes and clinical trials. They can also become leading advocates to catalyse advances in disease understanding, diagnosis and treatment 30 ; examples of patient advocacy organizations formed by diagnosed individuals include Prion Alliance, the Hypertrophic Cardiomyopathy Association and Hear See Hope.
Paediatric medicine. Although many genetic disorders are apparent at birth, several only manifest or are revealed in childhood. For example, retinoblastoma is often not present at birth but is a largely paediatric cancer that requires more aggressive screening to be detected 22 .
As another example, hearing impairment may not be sufficiently severe for detection during newborn screening or can develop and progress after birth (FIG. 1, Case  study 3) . Also, intellectual disability and autism are not apparent at birth and require ongoing evaluation during childhood and adolescence to properly determine the extent of effects on intellect and behaviour. Growth conditions 31 and other endocrinological disorders 32 also typically manifest in childhood. For these reasons, paediatricians must be adept at detecting paediatric diseases and at recognizing when the underlying causes are genetic, potentially requiring medical intervention, and alert parents regarding the risk to future children.
Adult medicine. Engagement of genomics in the adult population occurs most often in the context of: diagnostic germline testing for symptomatic individuals; tumour profiling to inform cancer treatment has grown, including monogenic disease risks such as hereditary cancer and inherited cardiovascular diseases, individuals have begun to pursue genomic sequencing to gain a more complete analysis of their own health risks. Some projects have been launched with the aim of data sharing to advance science (for example, the Personal Genome Project), whereas other projects are integrated into clinical practice and target healthy patients interested in learning about their own personal disease risks 41, 42 . Although DTC services focused initially on wealthy individuals, who were able to afford the high cost of genomic services, the falling costs of genomic sequencing increasingly enable access for the wider population interested in understanding and informing their health 43 . (TABLE 1) : genotyping tests for known disease or treatment-associated variants; diseasetargeted panel tests for genes known to be associated with the disorder or treatment; exome sequencing tests, which interrogate nearly all protein-coding regions; and genome sequencing tests, which interrogate nearly our entire genetic code including non-coding regions.
Challenges to clinical genomics
The most straightforward and high-yield tests that are performed today in genetic and genomic testing are diagnostic tests for monogenic diseases and certain cancer diagnostic tests. However, monogenic disease tests typically detect less than half of the aetiologies [44] [45] [46] [47] [48] [49] [50] [51] (FIG. 2) . In some cases, this low detection rate is attributable to the existence of both genetic and non-genetic causes of the illness, and a genetic test will never identify the non-genetic causes. However, in most cases, the primary failure is the absence of a complete understanding of the genetic underpinnings of a disease 52 . Indeed, in many families with clearly inherited disease we fail to detect the genetic aetiology owing to insufficient evidence to implicate variation in the gene or because of its occurrence in a regulatory region of the genome that is poorly understood functionally 52 . For somatic cancer testing, a genetic alteration that directs a treatment decision can be found in a subset of tumours [53] [54] [55] ; however, the cancer may recur with treatment resistance due to the continuously evolving genetic alterations that occur as the tumour grows. and prognosis; and genomic testing to inform ancestry, health risks and other traits. The first two occur largely within the clinical care setting, whereas the third has been the focus of the DTC market. There are many diseases with adult-onset symptoms for which an individual can seek diagnostic testing. Such diseases include cardiovascular disease (for example, arrhythmia, cardiomyopathy, aortic disease and very high cholesterol levels; FIG. 1 , Case study 4), cancer , hearing loss and vision loss, particularly if the disease is associated with a known or possible family history of disease. Although early diagnosis and/or strong family history of cancer may prompt hereditary cancer testing, cancers more often occur sporadically owing to somatically derived genetic alterations that are not inherited but occur in cells of the body 33 . Today, numerous genetic alterations have been identified in tumours that correlate with therapy response, such as epidermal growth factor receptor (EGFR) mutations in lung cancer, which predict response to tyrosine kinase inhibitors 34, 35 . Other examples include anaplastic lymphoma receptor tyrosine kinase (ALK) fusions in lung cancer (which predict response to crizotinib 36 ), HER2 (also known as ERBB2) mutations in breast cancer (which predict trastuzumab response 37, 38 ), the BRAF V600E mutation in melanoma (which confers sensitivity to vemurafenib 39 ), and socitrate dehydrogenase (NADP + ) 1 (IDH1) mutations in gliomas (which are associated with response to temozolomide 40 ). Widespread uptake of DTC testing to inform ancestry, health risks and other traits began with the introduction of high-throughput genotyping arrays that examine common genetic variation. However, as public awareness of health risks Apart from a few rare exceptions (for example, sickle cell anaemia, achondroplasia, and BRAF V600E mutations in skin cancer), most genetic tests for known disease-causing variants have low sensitivity. The reason for this lack of sensitivity is because most conditions are genetically heterogeneous, with multiple possible aetiologies and with many variants being unique to a family. For example, hundreds of variants in more than 50 genes are causative for hypertrophic cardiomyopathy 44 . As a result, most monogenic disease tests require sequencing approaches, either panel-based or exome or genome sequencing. Although more costly and comprehensive, the clinical sensitivities of exome and genome sequencing are not always higher than a disease-focused panel test. In some cases, clinical sensitivities of exome and genome sequencing may be lower depending on the contribution of CNVs to the disease and whether the test includes CNV detection through built-in analysis approaches or adjunct platforms 56, 57 . Given the higher costs compared with conventional genetic tests and the fear of potential downstream health care costs due to the return of secondary genetic findings, exome and genome sequencing services are particularly poorly covered by health insurance plans. This issue has slowed the uptake of these broader tests. However, as the technical and interpretive barriers are gradually overcome and laboratories offer genomic approaches at similar costs to panel-based tests, these comprehensive approaches will soon dominate the market.
The challenges of variant interpretation.
Regardless of the platform chosen or indication for testing, all genetic tests come with one major liability: the challenge of interpreting the genetic variants identified during testing (FIG. 1, Case study 5 ). An analysis of data in ClinVar, a database hosted by the NIH's National Center for Biotechnology Information 58 , quantifies this challenge, with 17% of variants interpreted by more than one submitter showing a difference in variant classification 59 . It is unsurprising that variant interpretation is a challenge; our genomes are littered with variation -typically four to five million variants per individual, with more than 10,000 among gene-coding regions 6 -yet there is no dictionary to define the 'meaning' of each variant. Furthermore, many of the variants causative for disease are extremely rare or unique to variant interpretation is through the sharing of variants in a common database. Such a database can enable crowdsourcing of the labour-intensive effort of gathering data as well as identifying differences in interpretation and resolution of those differences between laboratories and by experts in the relevant fields 61, 63 . With 67% of submitters coming from outside the United States (D. Maglott, personal communication), the ClinVar database 58 robustly serves a data aggregation purpose for the international community. The NIH-funded ClinGen (Clinical Genome Resource) programme is forming and approving panels that convene relevant experts to agree on approaches to variant interpretation and to ensure that the relevant variants are being interpreted to those standards 59 . However, this application of expert curation will take time: only ~4% of variants have been reviewed by experts in ClinVar at the time of writing 64 , therefore the community must still rely on laboratories to share their knowledge with each other before experts can weigh in.
For each variant found in an individual, curators scour the literature, searching for evidence: a few segregations in a pedigree, detailed phenotyping in a patient, a de novo occurrence in a parent-offspring trio, a single data point from a functional assay. However, such information is typically reported in an unstructured, non-systematic manner, largely embedded in the unstructured figures and detailed individuals. Although recent standards for genetic interpretation have been published 60 , and will no doubt help to prevent the most egregious differences in interpretation, even experts using such standards differ in their interpretations, particularly before consensus efforts are applied 61 . As of January 2017, more than 250,000 unique interpreted variants had been submitted by more than 630 laboratories to ClinVar. However, one-third of those variants were submitted with an uncertain significance classification. More importantly, we know from the Exome Aggregation Consortium (ExAC) that more than 7.4 million variants have been identified in gene-coding regions 62 , most of which have no entry in ClinVar. Applying a 1% frequency filter, which is typical for monogenic disease analysis, only eliminates 1% of the variants from consideration. Moreover, comparison across individuals shows that each individual harbours more than 60 coding variants that are found only in one in 60,000 or more individuals 62 . This rarity creates enormous challenges for variant interpretation.
So what then is the path to freedom from this deluge of uninterpretable variants? The answer, in my opinion, lies with widespread open data-sharing and the standardization and structuring of data for scaled analyses.
Data sharing to advance genomics
To ensure efficient and accurate diagnosis for patients, it is becoming increasingly clear that the best path to improved DNA Figure 2 | Detection rates across a selection of molecular diagnostic tests. These data are from multiple studies spanning several indications [44] [45] [46] [47] [48] [49] [50] [51] . The specific detection rate can vary based on the specificity of the clinical presentations and the comprehensiveness of the test panel. 
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text of published manuscripts. Imagine instead a world in which a common data model describes the evidence types for variants, and such evidence is systematically collected in databases connected through a federated network of laboratories and health care systems. Each source shares the individual-level and family data, the results of functional analyses or other data sources that are useful in the evidence-based interpretation of DNA variation. Imagine no resource barriers to the storage and computing power of an exponentially scaling quantity of genotype and phenotype data, and a plethora of well-trained computational biologists poised to turn raw data into an informed understanding of human health and disease risk. We will get there. There are many mechanisms to support data sharing of both variant-level data described above and individual-level data that include genetic or genomic analyses and phenotype; centralized databases and federated systems are examples of such mechanisms (FIG. 3) . In a centralized model, groups submit their data to a single physically located database, such as ClinVar (for variant-level claims), the database of Genotypes and Phenotypes (dbGaP) or the European GenomePhenome Archive (EGA) (for individuallevel data). In a federated model, multiple physical databases exist, located in different sites but connected through an application programming interface. The database schemas in a federated network can be the same or different. What must be agreed upon are the fields and structure of the data sent through the application programming evidence). As variant-level data are not considered individual data and therefore not subject to the Privacy Rule of HIPAA (the Health Insurance Portability and Accountability Act of 1996), the data can be easily shared and deposited in the public domain 66 . And because comparison of multiple clinical interpretations of a variant is helpful to build confidence in a variant interpretation or note discordance, the aggregation of all clinical assertions on a variant is vital for this type of database. By contrast, the individual-level data (genotype and phenotype) from which a variant was originally identified are also very useful to access during the interpretation of a variant. However, one can provide links from variant-level databases to the sources of individual-level data, which could then be accessed only as needed and through secure interfaces designed to protect patient privacy.
Indeed one of the major challenges to advancing our field is the careful balance of storing and sharing individual genomic and health data in an accessible manner, while protecting the privacy of individuals. Although there is no perfect solution that optimizes sharing yet prevents privacy breaches, the use of federated approaches can reduce concerns over misuse of shared data 67 . Furthermore, proper consent and direct engagement of individuals in sharing their own data is likely to positively influence data sharing as individuals are empowered to make their own decisions about the risks and benefits of giving access to their genomic data 68, 69 .
Considerations of the return of results.
Although testing for genomic risk is becoming more commonplace, there remains ethical debate over screening children for genetic disease risk 70 . Surveys of parents suggest an interest in using genomics technologies to screen newborn babies 24 , although pursuit of such approaches remains uncommon. The low uptake is also due to concerns of genomicists and families over how to deal with the identification of untreatable disease risks that could have a negative impact on the child and their future autonomy; for example, leading to discrimination regarding a child's eligibility for disability and long-term care insurance policies 71, 72 . The same considerations are relevant when considering paediatric care.
Most children in the United States have routine screening visits with a health care provider to assess their health interface, which can be constructed specifically to support a defined need. For example, investigators wishing to solve the causes of rare diseases are now using the federated Matchmaker Exchange network, which supports queries between databases on phenotypes and candidate genes to match rare disease cases from around the world 65 . So which is better: federated or centralized? The answer is not one or the other but depends on the nature of the data and the purpose of the database. If the data being shared are subject to strict patient privacy and security rules, it may be that allowing each group to physically store and protect the data according to their own laws and other restrictions, and then connecting those databases in a federated model, is the better solution. Conversely, if such constraints are not a concern and the ability to combine and compare data and display them in a coordinated manner is critically important, such as the sharing of variant-level data in ClinVar or aggregated allele frequency data in ExAC, then a centralized database makes more sense.
A specific example of how centralized and federated systems can be integrated for optimal use is in databases of definitions to support variant interpretation. As described above, ClinVar is primarily a variant-level database. The primary accession is a variant with defined attributes (genomic coordinates to describe location, nomenclature recommended by the Human Genome Variation Society to define the functional impact of genes and transcripts, interpretations of clinical significance, publication citations and other supporting In a centralized database model, submitters send data to a single central database. In a federated system, the data remain in the originating database with queries supported through application programming interfaces (APIs).
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on an annual basis. Care includes, for example, vaccinations, hearing and vision screening, as well as examinations to ensure appropriate physical and behavioural milestones are being achieved. It is a logical extension that the use of genomic screening to inform health risks for a child would have equal merit to that for a newborn baby. For example, retinoblastoma, one of the most common childhood cancers, is largely curable with vision retention if diagnosed early but requires ophthalmological screening under anaesthesia every 3-4 weeks after birth 22 . Newborn genomic screening would facilitate the identification of babies at risk and enable appropriate intervention to ensure a healthy outcome. However, it is important to note that detection of a pathogenic variant in a newborn baby, young child or even an adult, rarely provides an accurate assessment of the likelihood that the individual will develop the disease over their lifetime. Penetrance can range from low to high [73] [74] [75] [76] [77] (FIG. 4) ; however, most data on the penetrance of individual genetic disorders are obtained from families in whom the disease is present. To form an unbiased view on disease penetrance will require extremely large studies of genotype-first approaches followed by clinical follow-up to identify the existence or development of disease over time, such as the All of Us SM research programme of the
Precision Medicine Initiative
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. This initiative will enable a more accurate determination of disease risk and inform appropriate treatment and management strategies based on those risks. Meanwhile, we must proceed forward despite the absence of a completely informed view of penetrance. Indeed, the management strategies for certain disorders may not differ whether disease risk is 90% or 10%. For example, if a newborn baby is diagnosed as having a pathogenic variant in ELN (which encodes elastin), putting the newborn baby at risk of subaortic stenosis and subsequent sudden cardiac death 78 , it is highly unlikely that the awareness of incomplete penetrance will lead to a decision not to have an echocardiogram to detect a potential structural malformation that can be corrected by surgical intervention 79 . In summary, although we have much to learn in genomics and the true risks of diseases identified, we are increasingly armed with clear examples of the clinical utility of genome sequencing, making it likely for this approach to be embraced as a complementary and expanded method to traditional preventive medicine approaches. already tracking the status of their own variants in ClinVar and actively engaging in data-sharing activities to advance understanding of their own diseases and genomic variants [80] [81] [82] . Finally, we must continue to navigate additional, often country-specific, barriers to the widespread use of genomics, such as the impact on employment, as well as health, life and long-term disability insurance policies. A detailed review of the laws and insurance policies across many countries is beyond the scope of this Essay; however, we must recognize the impact, whether based on real or perceived concerns, that these forces have on the uptake of genomics 83 . To use genomics effectively, we must support the delivery of information at the point of care. For example, if a physician receives a high cholesterol level result for a patient, the electronic health record system could prompt the physician to either order a genetic test or query genomic data residing directly in the patient's medical record. If a physician orders a drug that is contraindicated or the dose of which should be adjusted based on an individual's genetic variants, drug choice or dosage could be automatically adjusted. If a bone marrow transplant is needed, databases of individuals willing to serve as donors could be queried around the world to instantly identify matches. Meanwhile, data on patient phenotypes, medication usage and treatment outcomes could be collected continuously and stored, with access enabled through federated queries and tabulations as our health care system evolves.
An optimized, learning health care system will not happen on its own, particularly given the skyrocketing cost Looking to the future Although many challenges exist in scaling genomics as a primary tool in health care, these barriers are gradually breaking down as costs are reduced and resources to support the generation and sharing of genomic knowledge are improved. But what else remains to be overcome to effectively incorporate genomics into the daily practice of medicine at a scale that makes genomics an aspect of every individual's life?
In addition to the core challenges described above, other secondary challenges are likely to hamper the widespread expansion of precision medicine. These challenges include the need to expand the workforce of professionals trained to understand, deliver and incorporate genetics into the care of patients. Physicians must be more comprehensively trained in genetics, particularly with respect to diseases and relevant testing approaches in their areas of specialty practice. We must expand training programmes to produce more genetic counsellors able to spend the necessary time with patients to answer complex questions around disease risk and the ever-changing knowledge base that accompanies each variant identified in a patient. Moreover, experts are needed to guide individuals to consider the sharing of their genomic and health information with family members and the broader community to advance knowledge and build evidence. Although genetic counsellors will undoubtedly be critical in this space, it will also become increasingly important to facilitate knowledge-building through online tools and for individuals to take an active role in educating themselves about genetics. Individuals are [73] [74] [75] [76] [77] . The midpoint was used for data expressed as a range. Nature Reviews | Genetics of health care. We must design a system that saves resources while improving outcomes. The two are often at odds with each other, but with a continued focus on evidence-based medicine, and payment for outcomes not services, and the provision of real-time support for decision-making as well as coordinated care delivery, we may be able to achieve cheaper, more cost-effective care, incorporating genomics in a manner that adds value without increasing overall health care costs.
